anti-naloxone hydrazone | 91797-50-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: anti-naloxone hydrazone
• 英文别名: Naloxone hydrazone；Naloxone-6-hydrazone；(4R,4aS,7E,7aR,12bS)-7-hydrazinylidene-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
• CAS: 91797-50-1
• 化学式: C₁₉H₂₃N₃O₃
• 分子量: 341.41
• InChiKey: XQQRNWNMEFUSMN-UTWDOOMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  91.3
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-hydroxyestra-1,3,5(19)-trien-17-one 17-hydrazone 、 anti-naloxone hydrazone 以 乙醇 为溶剂， 以82.3%的产率得到estrone-naloxone azine
  参考文献：
  名称：

  syn-Anti isomerism in the opiate hydrazones and azines derived from naloxone, naltrexone, and oxymorphone

  摘要：

  DOI：

  10.1021/jo00194a029

文献信息

• Methods and compositions to prevent addiction
  申请人：FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

  公开号：US11045465B2

  公开（公告）日：2021-06-29

  Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject comprising, administering a therapeutic amount of the neurological stimulant and administering an antagonist of the kappa opioid receptor, to thereby reduce or prevent the development of aversion to the CNS stimulant in the subject. Also disclosed is a method of reducing or preventing the development of addiction to a CNS stimulant in a subject, comprising, administering the CNS stimulant and administering a mu opioid receptor antagonist to thereby reduce or prevent the development of addiction to the CNS stimulant in the subject. Also disclosed are pharmaceutical compositions comprising a central nervous system stimulant and an opioid receptor antagonist. Examples of central nervous system stimulants (such as methylphenidate) and opioid receptor antagonists (such as naltrexone) are provided.

  本文公开了一种减少或防止受试者对中枢神经系统兴奋剂产生厌恶感的方法，包括施用治疗量的神经兴奋剂和施用卡巴阿片受体拮抗剂，从而减少或防止受试者对中枢神经系统兴奋剂产生厌恶感。还公开了一种减少或防止受试者对中枢神经刺激物成瘾的方法，包括施用中枢神经刺激物和施用μ阿片受体拮抗剂，从而减少或防止受试者对中枢神经刺激物成瘾。还公开了包含中枢神经系统兴奋剂和阿片受体拮抗剂的药物组合物。提供了中枢神经系统兴奋剂（如哌醋甲酯）和阿片受体拮抗剂（如纳曲酮）的实例。
• USE OF OPIOID RECEPTOR ANTAGONISTS
  申请人：DSM IP Assets B.V.

  公开号：EP1926490A2

  公开（公告）日：2008-06-04
• USE OF SELECTIVE DELTA-OPIOID RECEPTOR ANTAGONISTS AND SPECIFIC SENSORY RECEPTOR LIGANDS
  申请人：Avant Derma PTE. Ltd.

  公开号：EP2945627A1

  公开（公告）日：2015-11-25
• Use of opioid receptor antagonists
  申请人：Beumer Raphael

  公开号：US20090041687A1

  公开（公告）日：2009-02-12

  The present invention relates to a new use of opioid receptor antagonists. More particularly, the present invention relates to the use of opioid receptor antagonists for the manufacture of topical compositions for suppression of melanin formation in the human skin; to topical, particularly cosmetic, compositions for suppression of melanin formation in the human skin comprising an opioid receptor antagonist; and to a method of lightening human skin and/or treatment of pigmentation disorders which comprises topically administering an effective amount of an opioid receptor antagonist to the appropriate skin area of a person in need of such treatment.
• METHODS AND COMPOSITIONS TO PREVENT ADDICTION
  申请人：Bhide Pradeep G.

  公开号：US20120302590A1

  公开（公告）日：2012-11-29

  Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject comprising, administering a therapeutic amount of the neurological stimulant and administering an antagonist of the kappa opioid receptor, to thereby reduce or prevent the development of aversion to the CNS stimulant in the subject. Also disclosed is a method of reducing or preventing the development of addiction to a CNS stimulant in a subject, comprising, administering the CNS stimulant and administering a mu opioid receptor antagonist to thereby reduce or prevent the development of addiction to the CNS stimulant in the subject. Also disclosed are pharmaceutical compositions comprising a central nervous system stimulant and an opioid receptor antagonist. Examples of central nervous system stimulants (such as methylphenidate) and opioid receptor antagonists (such as naltrexone) are provided.